Vertex Pharmaceuticals (VRTX) The 44th Annual William Blair Growth Stock Conference summary

Corporate strategy and innovation

• Focuses on serial innovation in diseases with high unmet need, validated targets, and efficient development pathways, prioritizing specialty areas and reinvesting in R&D.

• Adopts a disease-first approach, leveraging multiple modalities (mRNA, cell therapy, small molecules, antibodies) as tools to transform or cure targeted diseases.

• Strategy since 2014 has led to significant advancements, especially in cystic fibrosis (CF), with a pipeline built on both internal and external innovation.

• About 40% of the clinical pipeline (excluding Alpine) comes from business development, with the rest from internal R&D.

• Largest acquisition to date was Alpine Immune Sciences for nearly $5 billion, aligning with the core R&D philosophy.

Pipeline highlights and recent advancements

• Serial innovation in CF includes Kalydeco, Orkambi, Symdeko, Trikafta, and the recently filed vanzacaftor, aiming for higher efficacy and broader patient reach.

• Casgevy, the first CRISPR-Cas9-based therapy, approved in multiple regions, targets sickle cell and beta thalassemia, with ongoing efforts to expand eligibility via gentler conditioning.

• Suzetrigine (VX-548), a non-opioid pain medicine, is in rolling FDA submission with Fast Track and Breakthrough designations, aiming to fill the gap for effective, non-addictive pain relief.

• Type 1 diabetes programs use stem cell-derived islet cells, with three approaches: direct infusion (VX-880), encapsulation (VX-264), and hypoimmune gene editing, all progressing through clinical or preclinical stages.

• Alpine’s povotacicept (Povi), a dual APRIL/BAFF inhibitor, is phase III-ready for IgA nephropathy, with additional basket studies in other renal and B-cell-driven diseases.

Commercial and financial outlook

• Revenue growth in CF is driven by expanding to younger age groups, new geographies, and the upcoming vanzacaftor launch, which also offers lower royalty burdens.

• mRNA therapies in development could add 5,000–7,000 new CF patients, targeting those not eligible for current modulators.

• Casgevy launch is progressing as expected, with revenue recognized at infusion; patient scheduling may vary seasonally but is ultimately individualized.

• Free cash flow exceeds $3 billion, supporting continued investment in innovation and selective acquisitions aligned with the core strategy.

• Near-term goals include expanding CF leadership, launching new products in diversified areas, advancing mid- and late-stage pipeline assets, and sustaining financial performance.